Jacobs & Co. CA Acquires 424 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Jacobs & Co. CA boosted its holdings in shares of Laboratory Co. of America Holdings (NYSE:LHFree Report) by 1.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,630 shares of the medical research company’s stock after buying an additional 424 shares during the quarter. Jacobs & Co. CA’s holdings in Laboratory Co. of America were worth $5,162,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Mendota Financial Group LLC acquired a new stake in Laboratory Co. of America in the 4th quarter worth approximately $29,000. Bruce G. Allen Investments LLC bought a new stake in shares of Laboratory Co. of America during the 4th quarter worth $60,000. Disciplined Equity Management Inc. acquired a new position in Laboratory Co. of America in the 4th quarter valued at $68,000. Oakworth Capital Inc. raised its holdings in Laboratory Co. of America by 48.1% in the 4th quarter. Oakworth Capital Inc. now owns 308 shares of the medical research company’s stock worth $70,000 after acquiring an additional 100 shares during the period. Finally, Planned Solutions Inc. bought a new stake in Laboratory Co. of America during the fourth quarter valued at about $76,000. 95.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 250 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $204.13, for a total transaction of $51,032.50. Following the completion of the transaction, the director now owns 15,972 shares in the company, valued at approximately $3,260,364.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $210.83, for a total value of $421,660.00. Following the sale, the executive vice president now directly owns 5,637 shares in the company, valued at approximately $1,188,448.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kerrii B. Anderson sold 250 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $204.13, for a total transaction of $51,032.50. Following the transaction, the director now owns 15,972 shares of the company’s stock, valued at $3,260,364.36. The disclosure for this sale can be found here. Insiders have sold a total of 18,469 shares of company stock worth $3,959,058 over the last ninety days. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Trading Down 0.4 %

Shares of NYSE:LH traded down $0.88 during mid-day trading on Tuesday, reaching $207.12. The stock had a trading volume of 75,377 shares, compared to its average volume of 746,103. The firm has a market cap of $17.46 billion, a PE ratio of 41.85, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05. The firm has a 50 day simple moving average of $201.92 and a two-hundred day simple moving average of $213.24. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $234.09.

Laboratory Co. of America (NYSE:LHGet Free Report) last posted its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.20. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm had revenue of $3.18 billion during the quarter, compared to analysts’ expectations of $3.12 billion. During the same period in the previous year, the firm earned $3.82 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. On average, research analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.39%. The ex-dividend date of this dividend was Friday, May 24th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.

Analysts Set New Price Targets

A number of research firms have recently commented on LH. Truist Financial dropped their price objective on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. StockNews.com cut Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. Argus upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a research note on Monday, March 25th. Robert W. Baird dropped their target price on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Finally, SVB Leerink initiated coverage on Laboratory Co. of America in a research report on Monday, February 26th. They issued an “outperform” rating and a $260.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and an average price target of $241.86.

Read Our Latest Stock Analysis on LH

Laboratory Co. of America Company Profile

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).

Further Reading

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LHFree Report).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.